NEW YORK ( TheStreet) -- Shares of Cornerstone Therapeutics (Nasdaq: CRTX) have taken a tremendous swing upward. The stock is trading at $7.05 as of four p.m. ET, 21.8% above Monday's closing price of $5.79. Volume is at 29,704, 0.9 times the daily average of 33,800.

Cornerstone has a market cap of $166.1 million and is part of the health care sector and drugs industry. Shares are unchanged year to date as of the close of trading on Monday.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of branded and generic pharmaceuticals primarily for the respiratory and related markets in the United States. The company has a P/E ratio of 49.2, above the average drugs industry P/E ratio of 45.7 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Cornerstone as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Cornerstone Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
null

If you liked this article you might like

Top Insider Trades: PSX YRCW CRTX IDIX

Top Insider Trades: PSX YRCW CRTX IDIX

5 Biotech Stocks Under $10 Making Big Moves

5 Biotech Stocks Under $10 Making Big Moves

4 Health Care Stocks Under $10 Close to Breakouts

4 Health Care Stocks Under $10 Close to Breakouts

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

31 Drugs Facing FDA Approval in 2012-2013

31 Drugs Facing FDA Approval in 2012-2013